Drug
Tepotinib clinical trials
Also written MSC2156119J, Tepmetko and EMD 1214063.
- studies test it
- 26
- open now
- 6
- in phase 3
- 1
- first study started
- 2009
Keep track of what changes. Save the tepotinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
26 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 13
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 11
Merck KGaA, Darmstadt, Germany (7) · EMD Serono Research & Development Institute, Inc. (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (3) · M.D. Anderson Cancer Center (2) · Institute of Cancer Research, United Kingdom (1) · Fondazione per la Medicina Personalizzata (1) · EMD Serono (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Trastuzumab (3) · Pertuzumab (3) · Vemurafenib (3) · Cobimetinib (3) · Alectinib (3) · Entrectinib (3) · Pemigatinib (3) · Pembrolizumab (2)
Studies
Open first, then newest update. How each study uses tepotinib is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07619339Written as Tepotinib
- Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib TreatmentRecruitingPhase 2Sehhoon ParkNCT06106802Written as Tepotinib
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06908993Written as Tepotinib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Tepotinib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Tepotinib
- Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ CarcinomaRecruitingPhase 1/2Hallym University Medical CenterNCT05439993Written as Tepotinib plus paclitaxel
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT06083857Written as Tepotinib
- Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingPhase 2EMD Serono Research & Development Institute, Inc.NCT02864992Written as Tepotinib
- POTENT - Tepotinib in Combination With Pembrolizumab in NSCLCActive, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT05782361Written as Tepotinib
- Tepotinib Hepatic Impairment TrialCompletedPhase 1EMD Serono Research & Development Institute, Inc.NCT03546608Written as Tepotinib
- A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain TumorsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05120960Written as tepotinib
- Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05213481Written as Tepotinib
- Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05203822Written as Tepotinib (HydroChloride hydrate)
- Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of TepotinibCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT04204902Written as Tepotinib 100 mg
- CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedPhase 1/2Criterium, Inc.NCT04739358Written as Tepotinib
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as Tepotinib
- Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran EtexilateCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03492437Written as Tepotinib
- Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03531762Written as Tepotinib
- Effect of Tepotinib on PK of CYP3A Substrate MidazolamCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03628339Written as Tepotinib
- Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT04515394Written as Tepotinib
See all 26 studies that test tepotinib →
Given in every arm · 2 — tepotinib is usual care beside what is tested
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingPhase 2SWOG Cancer Research NetworkNCT06031688Written as Tepotinib
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT03940703Written as Tepotinib
Codes
What other systems call tepotinib · ClinicalTrials.gg INT001334
- MeSH (NLM) C000707607tepotinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1IJV77EI07TEPOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2477103One source FDA
- Wikidata Q27088961tepotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88314TepotinibOne source FDA
- DrugBank DB15133One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707607 | tepotinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1IJV77EI07 | TEPOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2477103 | — | One source FDA |
| Wikidata | Q27088961 | tepotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88314 | Tepotinib | One source FDA |
| DrugBank | DB15133 | — | One source Wikidata |
Also registered as tepotinib hydrochloride (UNII VY5YX2TQ1F · RxNorm 2477104).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.